Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.47 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6178878 | 1.00 | ALDH1A1 (0.50) | ALDH1A1LMNAACHEFFAR1MAPT | |
| SCHEMBL11399936 | 0.90 | ACHE (0.60) | ALDH1A1ACHEFFAR1HPGDCYP3A4 | |
| SCHEMBL7398650 | 0.90 | ACHE (0.60) | ALDH1A1ACHEFFAR1HPGDCYP3A4 | |
| SCHEMBL13963557 | 0.85 | FFAR1 (0.47) | ALDH1A1LMNAACHEFFAR1HPGD | |
| SCHEMBL4445084 | 0.84 | TAAR1 (0.52) | ALDH1A1ACHEFFAR1HPGDCYP3A4 | |
| SCHEMBL3413768 | 0.83 | LMNA (0.55) | ALDH1A1LMNAFFAR1MAPTHPGD | |
| SCHEMBL1053042 | 0.82 | ACHE (0.53) | ALDH1A1LMNAACHEFFAR1MAPT | |
| SCHEMBL10548748 | 0.82 | CPA1 (0.50) | ALDH1A1ACHEFFAR1HPGDCYP3A4 | |
| SCHEMBL11154821 | 0.82 | FFAR1 (0.53) | ALDH1A1ACHEFFAR1HPGDCYP3A4 | |
| SCHEMBL14195420 | 0.82 | LMNA (0.51) | ALDH1A1LMNAMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10118169-B2 | Chiral ligand-based metal-organic frameworks for broad-scope asymmetric catalysis | THE UNIVERSITY OF CHICAGO (US) | 2018-11-06 | — | — | US | disclosed |
| US-20170173572-A1 | CHIRAL LIGAND-BASED METAL-ORGANIC FRAMEWORKS FOR BROAD-SCOPE ASYMMETRIC CATALYSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-06-22 | — | — | US | disclosed |
| US-20170173572-A1 | CHIRAL LIGAND-BASED METAL-ORGANIC FRAMEWORKS FOR BROAD-SCOPE ASYMMETRIC CATALYSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-06-22 | — | — | US | disclosed |
| US-20170173572-A1 | CHIRAL LIGAND-BASED METAL-ORGANIC FRAMEWORKS FOR BROAD-SCOPE ASYMMETRIC CATALYSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173572-A1 | CHIRAL LIGAND-BASED METAL-ORGANIC FRAMEWORKS FOR BROAD-SCOPE ASYMMETRIC CATALYSIS | POF1B, FGFR1, COASY | ALDH1A1 861/4885LMNA 3689/4885ACHE 2006/4885 |
| US-10118169-B2 | Chiral ligand-based metal-organic frameworks for broad-scope asymmetric catalysis | POF1B, FGFR1, COASY | ALDH1A1 861/4885LMNA 3689/4885ACHE 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.